Drug Discovery

GSK exercises option on phase I/II NY-ESO T-cell therapy

GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).

PATH boosts leadership in developing and introducing urgently needed vaccines

PATH has received a $120m grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.

Avadel secures exclusive rights to nocturia candidate Noctiva in US and Canada

Avadel Pharmaceuticals has entered into a license agreement with Serenity Pharmaceuticals, which grants Avadel the sole right to commercialize and further develop Noctiva in the US and Canada.

Tick saliva may reduce HIV-linked heart disease risk, says scientists

Scientists may have found a clue to why people living with HIV have double the likelihood of developing heart disease.

Genmab, Seattle Genetics to co-develop tisotumab vedotin for solid tumors

Genmab and Seattle Genetics announced that Seattle Genetics has exercised its option to co-develop tisotumab vedotin.

Regenxbio to buy US firm Dimension Therapeutics

Gene therapy firm Regenxbio has signed an agreement to acquire US-based firm Dimension Therapeutics.

Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody

Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.

Evotec completes Aptuit acquisition

German company Evotec has completed the acquisition of US-based Aptuit.

Vicarius Pharma secures $21.8m financing

Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.